CD30+Lymphoproliferative Disorders of the Skin.
Primary cutaneous CD30+lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of red or violaceous papulonodules. Patients with LyP are at an increased risk of a secondary malignancy. pcALCL is characterized by a solitary red to violaceous nodule or tumor larger than 20 mm. LyP is benign, is limited to the skin, and self-resolves, with a 5-year survival rate of 100%; pcALCL is limited to the skin and responsive to directed therapies, with a 5-year survival rate of over 95%. Aggressive chemotherapeutic regimens should be avoided.
Department of Dermatology, The Center for Cutaneous Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.
Maxwell B
MB
Sauder
Department of Dermatology, The Center for Cutaneous Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.
John T
JT
O'Malley
Department of Dermatology, The Center for Cutaneous Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: nleboeuf@partners.org.
Nicole R
NR
LeBoeuf
D018572:Disease-Free Survival; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D017731:Lymphomatoid Papulosis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D012307:Risk Factors; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D015996:Survival Rate
CD30(+); Cutaneous lymphoproliferative disorders; Lymphomatoid papulosis; Primary cutaneous anaplastic large cell lymphoma; Secondary cutaneous anaplastic large cell lymphoma